- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02300181
Effect of the Extract of the Flour Fermented With Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose
August 17, 2015 updated by: Fumiko Higashikawa, Hiroshima University
A Randomized, Double-blind, Placebo Controlled, Crossover Study to Determine the Effect of the Flour Fermentation Products by Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose Profile in Prediabetic Subjects.
The purpose of the present study is to evaluate the effect of the extract of the flour fermented with Bacillus subtilis var natto DC-15 on postprandial glucose level in subjects with prediabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hiroshima, Japan, 734-8551
- Hiroshima University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Fasting plasma glucose 110-125 mg/dL
Exclusion Criteria:
- Taking anti-diabetic drugs
- Taking drugs or functional food that may affect blood glucose level
- Pregnant or nursing a child
- Participation in any clinical trial within 90 days of the commencement of the trial
- Renal or hepatic dysfunction
- Heart disease
- History of severe disease and/or major surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo (flour)
5 placebo capsules for each test (4.88 kcal/5 cap)
|
|
|
EXPERIMENTAL: Bacillus subtilis var natto DC-15
5 experimental capsules for each test (4.96
kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in plasma glucose profile including AUC and Cmax after taking 50 g carbohidrate.
Time Frame: Overall 3 hours
|
Overall 3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (ACTUAL)
March 1, 2015
Study Completion (ACTUAL)
March 1, 2015
Study Registration Dates
First Submitted
November 20, 2014
First Submitted That Met QC Criteria
November 20, 2014
First Posted (ESTIMATE)
November 24, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
August 19, 2015
Last Update Submitted That Met QC Criteria
August 17, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- eki-1051
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prediabetes
-
Shifa International HospitalRecruitingPrediabetes | Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) | Prediabetes or DiabetesPakistan
-
Mayo ClinicRecruiting
-
Aga Khan UniversityLinnaeus University; Kenyatta UniversityRecruiting
-
Chonbuk National University HospitalCompletedPreDiabetes
-
National Yang Ming UniversityRecruiting
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Clinical Nutrition Research Centre, SingaporeSingapore Institute for Clinical SciencesCompleted
-
Northwestern UniversityAllianceChicago; Erie Family Health CentersCompleted
-
Ohio UniversityTouro University, CaliforniaCompletedPreDiabetes
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States